Nurix Therapeutics is a biotechnology company that is focused on the discovery, development, and commercialization of small molecule therapies that modulate the ubiquitin proteasome system (UPS) for the treatment of cancer and other diseases. The company's proprietary drug discovery platform is based on the use of DNA-encoded libraries (DELs) to identify small molecules that selectively bind to E3 ligases, which are key enzymes in the UPS. Nurix's lead drug candidate, NX-2127, is a first-in-class small molecule inhibitor of the CBL-B E3 ligase that is being developed for the treatment of solid tumors and hematological malignancies. The company was founded in 2013 and is headquartered in San Francisco, California.